Showing results (1321-1330 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|November 6, 2004
Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expressionLeticia Medina-Gundrum, Cesario Cerna, Lionel Gomez, et al.
Investigational New Drugs|November 6, 2004
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitorJohn L Marshall, Hedy Kindler, John Deeken, et al.
Investigational New Drugs|May 4, 2004
A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cellsValeria Gonzalez-Nicolini, Cornelia Fux, Martin Fussenegger
Investigational New Drugs|April 1, 1992
Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group studyS A Taylor, P Goodman, E D Crawford, et al.
Investigational New Drugs|September 1, 2005
Novel therapy in multiple myelomaAgustin Avilés, Natividad Neri, M Jesús Nambo, et al.
Investigational New Drugs|September 1, 2005
Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonistsDoris M Benbrook, Scott A Kamelle, Suresh B Guruswamy, et al.
Investigational New Drugs|September 1, 2005
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130Karen A Gelmon, Karl Belanger, Denis Soulieres, et al.
Investigational New Drugs|September 1, 2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancerJaffer A Ajani, Chris Takimoto, Carlos R Becerra, et al.
Investigational New Drugs|March 4, 2005
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell linesJürgen Sonnemann, Jennifer Gänge, K Saravana Kumar, et al.
Investigational New Drugs|March 4, 2005
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupG Goss, H Hirte, W H Miller, et al.
Pageof 372